Febuxostat

CAS 144060-53-7 27 current records 4 historicalSmall Molecule

Who holds supplier records for Febuxostat? 27 organisations hold a current record for Febuxostat: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (17), China (5) and Netherlands (1); not recorded for 4.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Febuxostat: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/febuxostat

Reading the evidence

  • 27 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    17 of the 23 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 15 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Febuxostat expires 8 Sept 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (27)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Febuxostat. Country is the organisation's recorded country, not necessarily the manufacturing site.

India17China5Netherlands1Country not recorded for 4
Need Febuxostat sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (4)

Organisations whose Type II DMFs for Febuxostat are no longer active. These show a past filing, not current supply.

Show all 4 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (26 listed products contain Febuxostat). The latest listed patent expires 8 Sept 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Febuxostat is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1164729).

Chemical identity

IUPAC name
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
Canonical SMILES
CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
InChIKey
BQSJTQLCZDPROO-UHFFFAOYSA-N
Synonyms
Adenuric, Febuxostat, Febuxostat krka, Febuxostat mylan, Febuxostat viatris (previously febuxostat mylan), NSC-758874, TMX-67, Uloric, Tei 6720, Tei-6720, TMX 67, Zurig

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Xanthine Oxidase Inhibitor
Mechanism of action
Xanthine Oxidase Inhibitors

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Febuxostat?

27 organisations hold an active US FDA Type II Drug Master File or a CEP for Febuxostat: LUPIN MANUFACTURING SOLUTIONS LTD, MSN Organics Private Limited (India), Alembic Pharmaceuticals Limited (India), AMI LIFESCIENCES PRIVATE LTD (India), APITORIA PHARMA PRIVATE LTD (India), CHONGQING SHENGHUAXI PHARMACEUTICAL CO LTD, DASAMI LAB PRIVATE LTD (India) and Dr. Reddy's Laboratories Ltd. (India), and 19 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Febuxostat Drug Master Files are active?

LUPIN MANUFACTURING SOLUTIONS LTD (DMF 33757, 26582), MSN Organics Private Limited (DMF 31340, 26289), Alembic Pharmaceuticals Limited (DMF 26417), AMI LIFESCIENCES PRIVATE LTD (DMF 37996), APITORIA PHARMA PRIVATE LTD (DMF 31397), CHONGQING SHENGHUAXI PHARMACEUTICAL CO LTD (DMF 26043), DASAMI LAB PRIVATE LTD (DMF 39349) and Dr. Reddy's Laboratories Ltd. (DMF 24822) and 19 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Febuxostat records mean?

4 organisations have only inactive Type II DMFs for Febuxostat. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Febuxostat?

Yes. The latest patent listed for an approved US product containing Febuxostat expires 8 Sept 2031, across 26 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Febuxostat supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Febuxostat?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.